Unlike companies that offer whole exome sequencing (WES) or genetic panel-based testing, Geval leverages low-coverage sequencing (LCS) to provide broader, cost-effective insights into genetic predisposition. The LCS technology also allows screening based on long-read sequencing at an affordable price. Long-read sequencing technology can identify cancer and other disease-causing structural variants in the genome that the currently popular short-read sequencing cannot offer. Geval also specializes in integrating microbiome analysis into personalized treatment strategies. Geval and Dhiyo Healthcare Analytics, which has a patent in identifying colorectal cancer from the microbiome, are partnering with the world's largest diabetic hospital, Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders (BIRDEM), to integrate genetics and microbiome data for personalized nutrition guidance for type-2 diabetic patients. Key Differentiators include:

Comprehensive Risk Assessment using LCS: Geval specializes in Genomic risk scores from LCS, which aggregate multiple genetic variants to provide more accurate risk prediction than single-gene or panel-based tests.

Novel Risk Assessment using LCS and Long-read sequencing: Geval specializes in identifying structural variants using LCS, which provides more accurate risk prediction for cancer and other complicated diseases.

Microbiome Analysis: Geval specializes in analyzing microbiome data to diagnose colorectal cancer.

Microbiome-Integrated Analysis: While most genetic testing companies focus solely on genomic data, Geval incorporates microbiome analysis to offer a holistic approach to disease risk, particularly for colorectal cancer and metabolic disorders.

Personalized Nutrition Guidance: Geval's approach extends beyond genetic testing by translating genomic and microbiome data into actionable dietary recommendations, particularly for conditions such as type 2 diabetes.

Cost-Effective and Scalable Solutions: Unlike WES, which requires high sequencing depth and is often expensive, LCS provides essential genetic insights at a lower cost, making it suitable for large-scale patient screening.

Genetic testing, including the use of Genomic risk scores, plays a vital role in understanding breast cancer risk. Genomic risk scores consider multiple genetic factors to estimate an individual's likelihood of developing breast cancer. By examining these genetic markers, doctors can provide personalized insights into a person's susceptibility to the disease. This knowledge helps individuals make informed decisions about screenings, preventive measures, and healthcare management. Genetic testing with Genomic risk scores empowers people to take charge of their health and take proactive steps to reduce breast cancer risk. If you have concerns about breast cancer, discussing genetic testing options with a healthcare professional can provide valuable guidance tailored to your unique genetic makeup.

Through a comprehensive analysis of various genetic factors, this approach provides a nuanced understanding of the complex interplay contributing to prostate cancer risk. Genomic risk scores, unlike single-gene testing, take into account a multitude of genetic variations, offering a more holistic assessment. By assessing the cumulative impact of these genetic markers, healthcare professionals can identify individuals who might not show mutations in well-known prostate cancer-related genes but still possess an elevated risk. This personalized insight empowers individuals and their healthcare providers to make informed decisions about screening, prevention, and tailored management strategies. Genomic risk scores contribute to a proactive and precision-oriented healthcare approach, allowing for early intervention and enhanced disease management.

In 50% of gestational diabetes mellitus case, patients seems to have t2d in future. Our Genereveal t2d for GDM can analyze and assess a patient's condition for future t2d. By delving into an individual's genetic makeup, this approach offers a deeper understanding of the potential T2D risk following GDM. Armed with this knowledge, healthcare providers can offer personalized guidance, enabling proactive steps towards T2D prevention and tailored healthcare management for those who have experienced GDM. This innovative approach underscores the importance of precision medicine in addressing the unique health needs of GDM patients, aiming to pave the way for healthier futures.